Reddi Anand, Leeper Sarah C, Grobler Anneke C, Geddes Rosemary, France K Holly, Dorse Gillian L, Vlok Willem J, Mntambo Mbali, Thomas Monty, Nixon Kristy, Holst Helga L, Karim Quarraisha Abdool, Rollins Nigel C, Coovadia Hoosen M, Giddy Janet
Sinikithemba HIV/AIDS Clinic, McCord Hospital, Durban, South Africa.
BMC Pediatr. 2007 Mar 17;7:13. doi: 10.1186/1471-2431-7-13.
Few studies address the use of paediatric highly active antiretroviral therapy (HAART) in Africa.
We performed a retrospective cohort study to investigate preliminary outcomes of all children eligible for HAART at Sinikithemba HIV/AIDS clinic in KwaZulu-Natal, South Africa. Immunologic, virologic, clinical, mortality, primary caregiver, and psychosocial variables were collected and analyzed.
From August 31, 2003 until October 31, 2005, 151 children initiated HAART. The median age at HAART initiation was 5.7 years (range 0.3-15.4). Median follow-up time of the cohort after HAART initiation was 8 months (IQR 3.5-13.5). The median change in CD4% from baseline (p < 0.001) was 10.2 (IQR 5.0-13.8) at 6 months (n = 90), and 16.2 (IQR 9.6-20.3) at 12 months (n = 59). Viral loads (VLs) were available for 100 children at 6 months of which 84% had HIV-1 RNA levels < or = 50 copies/mL. At 12 months, 80.3% (n = 61) had undetectable VLs. Sixty-five out of 88 children (73.8%) reported a significant increase (p < 0.001) in weight after the first month. Eighty-nine percent of the cohort (n = 132) reported < or = 2 missed doses during any given treatment month (> 95%adherence). Seventeen patients (11.3%) had a regimen change; two (1.3%) were due to antiretroviral toxicity. The Kaplan-Meier one year survival estimate was 90.9% (95%confidence interval (CI) 84.8-94.6). Thirteen children died during follow-up (8.6%), one changed service provider, and no children were lost to follow-up. All 13 deaths occurred in children with advanced HIV disease within 5 months of treatment initiation. In multivariate analysis of baseline variables against mortality using Cox proportional-hazards model, chronic gastroenteritis was associated with death [hazard ratio (HR), 12.34; 95% CI, 1.27-119.71) and an HIV-positive primary caregiver was found to be protective against mortality [HR, 0.12; 95% CI, 0.02-0.88). Age, orphanhood, baseline CD4%, and hemoglobin were not predicators of mortality in our cohort. Fifty-two percent of the cohort had at least one HIV-positive primary caregiver, and 38.4% had at least one primary caregiver also on HAART at Sinikithemba clinic.
This report suggests that paediatric HAART can be effective despite the challenges of a resource-limited setting.
很少有研究涉及非洲地区儿童高效抗逆转录病毒疗法(HAART)的使用情况。
我们开展了一项回顾性队列研究,以调查南非夸祖鲁 - 纳塔尔省辛基特姆巴艾滋病毒/艾滋病诊所所有符合HAART治疗条件的儿童的初步治疗结果。收集并分析了免疫、病毒学、临床、死亡率、主要照顾者以及社会心理等方面的变量。
从2003年8月31日至2005年10月31日,151名儿童开始接受HAART治疗。开始HAART治疗时的中位年龄为5.7岁(范围0.3 - 15.4岁)。该队列开始HAART治疗后的中位随访时间为8个月(四分位间距3.5 - 13.5个月)。6个月时(n = 90),CD4%较基线的中位变化(p < 0.001)为10.2(四分位间距5.0 - 13.8),12个月时(n = 59)为16.2(四分位间距9.6 - 20.3)。100名儿童在6个月时可检测病毒载量,其中84%的儿童HIV - 1 RNA水平≤50拷贝/毫升。12个月时,80.3%(n = 61)的儿童病毒载量检测不到。88名儿童中有65名(73.8%)报告在第一个月后体重显著增加(p < 0.001)。该队列中89%(n = 132)的儿童在任何给定治疗月内报告漏服剂量≤2次(依从性> 95%)。17名患者(11.3%)更换了治疗方案;2名(1.3%)是由于抗逆转录病毒药物毒性。采用Kaplan - Meier法估计的一年生存率为90.9%(95%置信区间(CI)84.8 - 94.6)。13名儿童在随访期间死亡(8.6%),1名更换了服务提供者,无儿童失访。所有13例死亡均发生在治疗开始后5个月内患有晚期HIV疾病的儿童中。在使用Cox比例风险模型对基线变量与死亡率进行多变量分析时,慢性肠胃炎与死亡相关[风险比(HR),12.34;95% CI,1.27 - 119.71],且发现HIV阳性的主要照顾者对死亡有保护作用[HR,0.12;95% CI,0.02 - 0.88]。在我们的队列中,年龄、是否为孤儿、基线CD4%以及血红蛋白水平均不是死亡的预测因素。该队列中有52%的儿童至少有一名HIV阳性的主要照顾者,38.4% 的儿童至少有一名主要照顾者也在辛基特姆巴诊所接受HAART治疗。
本报告表明,尽管在资源有限的环境中存在挑战,但儿童HAART治疗仍可能有效。